遗传

• 遗传资源 •    

一例GPAA1基因复合杂合突变导致糖基磷脂酰肌醇生物合成缺陷15型的诊断和基因检测分析

钟为军1,陈亚军2,刘佳楠1,熊符1,钟蕊2   

  1. 1.南方医科大学基础医学院医学遗传学教研室,广州 510515

    2.广东省韶关市妇幼保健院产前诊断中心,韶关 512000

  • 收稿日期:2026-03-15 修回日期:2026-05-07 发布日期:2026-05-21
  • 基金资助:
    国家自然科学基金(32570722, 32370649)资助[Supported by the National Natural Science Foundation of China (32570722, 32370649)]

Diagnosis and genetic analysis of a case of Glycosylphosphatidylinositol biosynthesis deficiency 15 caused by compound heterozygous mutations of GPAA1

Weijun Zhong1, Yajun Chen2, Jianan Liu1, Fu Xiong1, Rui Zhong2   

  1. 1. Department of Medical Genetics, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China 2. Prenatal Diagnosis Center of Shaoguan Maternal and Child Health Hospital, Guangdong Province, Shaoguan 512000, China
  • Received:2026-03-15 Revised:2026-05-07 Online:2026-05-21

摘要:

糖基磷脂酰肌醇生物合成缺陷15型(glycosylphosphatidylinositol biosynthesis deficiency 15GPIBD15MIM:617810)是一种由GPAA1基因突变引起的常染色体隐性遗传代谢疾病,主要表现为全面性发育迟缓、智力障碍、早发性癫痫发作、肌张力低下及小脑萎缩等症状。本研究报道了1例被诊断为糖基磷脂酰肌醇生物合成缺陷15型的患儿,主要临床表现为发育不良、大脑功能障碍。利用全外显子测序技术对患者及其父母进行基因检测分析发现,该患儿的GPAA1基因存在复合杂合突变c.1288C>Tp.P430S)和c.1621C>Tp.R541W),其父亲携带GPAA1基因的c.1288C>Tp.P430S)突变,其母亲携带GPAA1基因的c.1621C>Tp.R541W)突变。对这些突变位点进行有害性预测、保守性分析及蛋白质结构预测分析表明,这些突变均是有害的且高度保守的突变位点,突变后蛋白质的二级和三级结构均存在明显变化,提示这些突变可能对蛋白功能产生影响。进一步构建含GPAA1基因c.1288C>Tp.P430S)与c.1621C>Tp.R541W)的质粒表达载体,分别转染至HEK293T细胞,发现当两种突变质粒共转时,GPAA1基因的mRNA表达水平显著上升,但其蛋白表达水平显著下降。蛋白亚细胞定位结果分析显示突变前后的蛋白亚细胞定位没有改变。本研究报道了1例由GPAA1基因新发现的复合杂合突变引起的GPIBD15,其致病机制可能与突变蛋白的结构改变和表达量降低有关,扩展了GPAA1基因的变异图谱,有助于GPIBD15患者的早期诊断与遗传咨询。

关键词: 糖基磷脂酰肌醇生物合成缺陷15型, GPAA1基因, 变异图谱, 遗传咨询

Abstract:

Glycosylphosphatidylinositol biosynthesis deficiency 15 (GPIBD15, MIM: 617810) is an autosomal recessive inherited metabolic disorder caused by mutations in the GPAA1 gene. It is primarily characterized by global developmental delay, intellectual disability, early-onset epileptic seizures, hypotonia, and cerebellar atrophy. In this study, we reported a child diagnosed with GPIBD15 whose main clinical manifestations included dysplasia and cerebral dysfunction. We performed whole-exome sequencing on the patient and his parents. The patient was found to harbor compound heterozygous mutations c.1288C>Tp.P430S) and c.1621C>Tp.R541W) in the GPAA1 gene. The c.1288C>Tp.P430S) variant was inherited from the father, while the c.1621C>Tp.R541W) variant was inherited from the mother. Pathogenicity prediction, evolutionary conservation analysis and protein structure prediction analysis of these mutation sites showed that the variants are deleterious and located at highly conserved residues. These mutations lead to obvious changes in the secondary and tertiary structures of the protein, suggesting that they may affect protein function. To further investigate their functional impact, we constructed plasmid expression vectors harboring the c.1288C>Tp.P430S and c.1621C>Tp.R541W mutations and transfected them into HEK293T cells. We observed that co-transfection of the two mutant constructs significantly increased GPAA1 mRNA expression levels, while the corresponding protein expression levels were markedly decreased. Subcellular localization analysis showed no apparent difference between the wild-type and mutant proteins. In conclusion, we report a case of GPIBD15 caused by two novel compound heterozygous mutations in the GPAA1 gene. The pathogenic mechanism may be associated with mutation-induced structural alterations and reduced protein expression. Our findings expand the mutational spectrum of GPAA1 and provide valuable insights for early diagnosis and genetic counseling of patients with GPIBD15.

Key words: glycosylphosphatidylinositol biosynthesis deficiency 15, GPAA1 , gene, mutational spectrum, genetic counseling